Literature DB >> 797492

Plasma level monitoring of anticonvulsants.

M J Eadie.   

Abstract

The plasma concentrations of anticonvulsant drugs, and of certain of their biologically active metabolites, tend to be proportionate to the antiepileptic effects of these drugs. Consequently, anticonvulsant drug levels in plasma are monitored to help guide the clinician in managing his patients' epilepsies. In making use of the measurements, the clinician needs to know the relation between plasma level and biological effect for the various drugs. He also needs to have some awareness of simple pharmacokinetic principles. These are important in deciding when plasma levels should be monitored in relation to the patients' clinical state, to the dosage interval, and to change in the dosage of anticonvulsant or other drug. The clinician also requires pharmacokinetic knowledge in altering anticonvulsant drug dosage in his patients, and in interpreting plasma anticonvulsant level data, particularly when the patient is concurrently suffering from non-neurological disease. The ability to monitor plasma anticonvulsant levels has appreciably improved the treatment of epilepsy, but to obtain maximum benefits from the method, both pharmacokinetic insight and clinical wisdom are required.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 797492     DOI: 10.2165/00003088-197601010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  77 in total

1.  Determination of plasma and cerebrospinal fluid levels of dilantin in the human.

Authors:  H M TRIEDMAN; R A FISHMAN; M D YAHR
Journal:  Trans Am Neurol Assoc       Date:  1960

2.  The metabolic conversion of 5, 5-diphenyl hydantoin to 5-(p-hydroxyphenyl)-5-phenyl hydantoin.

Authors:  T C BUTLER
Journal:  J Pharmacol Exp Ther       Date:  1957-01       Impact factor: 4.030

3.  Protein binding of diphenylhydantoin and desmethylimipramine in plasma from patients with poor renal function.

Authors:  M M Reidenberg; I Odar-Cederlöf; C von Bahr; O Borgå; F Sjöqvist
Journal:  N Engl J Med       Date:  1971-07-29       Impact factor: 91.245

4.  Abnormal pharmacokinetics of phenytoin in a patient with uraemia.

Authors:  I Odar-Cederlöf; P Lunde; F Sjöqvist
Journal:  Lancet       Date:  1970-10-17       Impact factor: 79.321

5.  Gas chromatographic determination of barbiturates after extractive methylation in carbon disulfide.

Authors:  H Ehrsson
Journal:  Anal Chem       Date:  1974-06       Impact factor: 6.986

6.  The relationship of the anticonvulsant properties of primidone to phenobarbital.

Authors:  B B Gallagher; D B Smith; R H Mattson
Journal:  Epilepsia       Date:  1970-09       Impact factor: 5.864

7.  Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses.

Authors:  M Eichelbaum; K Ekbom; L Bertilsson; V A Ringberger; A Rane
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

8.  Phenylethylmalonamide (PEMA). An important metabolite of primidone.

Authors:  I P Baumel; B B Gallagher; R H Mattson
Journal:  Arch Neurol       Date:  1972-07

9.  The metabolism of diphenylhydantoin (Dilantin) following once-daily administration.

Authors:  R A Buchanan; A W Kinkel; J R Goulet; T C Smith
Journal:  Neurology       Date:  1972-02       Impact factor: 9.910

10.  Plasma anticonvulsant concentrations during pregnancy.

Authors:  C M Lander; V E Edwards; M J Eadie; J H Tyrer
Journal:  Neurology       Date:  1977-02       Impact factor: 9.910

View more
  22 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Therapeutic drug monitoring--antiepileptic drugs.

Authors:  M J Eadie
Journal:  Br J Clin Pharmacol       Date:  1998-09       Impact factor: 4.335

Review 3.  Therapeutic drug monitoring in saliva.

Authors:  M Danhof; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

4.  Poor correlation between single-dose data and steady-state kinetics for phenobarbitone, primidone, carbamazepine and sodium valproate in children during monotherapy. Possible reasons for the lack of correlation.

Authors:  J A Armijo; J L Herranz; R Arteaga; R Valiente
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

Review 5.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

6.  Recent advances in drug therapy for epilepsy.

Authors:  J Bruni
Journal:  Can Med Assoc J       Date:  1979-04-07       Impact factor: 8.262

7.  Suppression of LPS-induced matrix-metalloproteinase responses in macrophages exposed to phenytoin and its metabolite, 5-(p-hydroxyphenyl-), 5-phenylhydantoin.

Authors:  Ryan Serra; Abdel-Ghany Al-Saidi; Nikola Angelov; Salvador Nares
Journal:  J Inflamm (Lond)       Date:  2010-09-15       Impact factor: 4.981

8.  Clinical significance of the trimethadione tolerance test in chronic hepatitis: a useful indicator of hepatic drug metabolizing capacity.

Authors:  M Abei; E Tanaka; N Tanaka; Y Matsuzaki; T Ikegami; A Ishikawa; T Osuga
Journal:  J Gastroenterol       Date:  1995-08       Impact factor: 7.527

Review 9.  Optimisation of antiepileptic drug therapy. The importance of serum drug concentration monitoring.

Authors:  E Yukawa
Journal:  Clin Pharmacokinet       Date:  1996-08       Impact factor: 6.447

Review 10.  Clinical pharmacokinetics of carbamazepine.

Authors:  L Bertilsson
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.